Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Scott Stecher"'
1
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal function
Autor: Thomas Marbury, Scott Stecher, Daniel Ries, Dong Wei, Doug Kerr, Mark Rogge, Yingwen Dong, Ping He, Wildon Farwell
Publikováno v: Journal of Clinical Pharmacology
This phase I, open-label, single-dose study evaluated the pharmacokinetics, safety, and tolerability of renally excreted drug dexpramipexole in subjects with normal and impaired renal function, i.e. mild, moderate, severe renal impairment, or end-sta
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa86f5331bc6e031c26444cc9f0179c7
https://doi.org/10.1002/jcph.353
Zobrazit plný text záznamu
2
Chiral liquid chromatography-tandem mass spectrometry assay to determine that dexpramipexole is not converted to pramipexole in vivo after administered in humans
Autor: Scott Stecher, Chichih Wu, Liyu Yang, Dong Wei, Ping He, Doug Kerr
Publikováno v: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 971
Dexpramipexole (DEX) was being investigated in clinical studies for the treatment of amyotrophic lateral sclerosis (ALS). To monitor the potential chiral interconversion of dexpramipexole to pramipexole (PPX) in vivo, a highly sensitive and selective
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66ca5731bf0bc65efe30f88c47b6938
https://pubmed.ncbi.nlm.nih.gov/25289790
Zobrazit plný text záznamu
3
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function
Autor: Ali Seddighzadeh, Jaya Goyal, Ivan Nestorov, Scott Stecher, William B. Smith, Serena Hung, Mark Matson, Xiao Hu, Ying Zhu, Thomas Marbury
Publikováno v: Journal of Clinical Pharmacology
Peginterferon beta-1a was efficacious in a Phase 3 relapsing multiple sclerosis trial, and its safety profile was consistent with other beta interferons. This study evaluated the impact of renal impairment on the pharmacokinetics and pharmacodynamics
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7d50e6afd948347d848e66e60a9fcbc
https://pubmed.ncbi.nlm.nih.gov/25187030
Zobrazit plný text záznamu
4
Pharmacokinetics of oral tonapofylline and its acyl-glucuronide metabolite in patients with mild and moderate hepatic impairment
Autor: Kenneth C. Lasseter, Thomas Marbury, Daniel Freedman, Dong Wei, Liang-Shang Gan, Amy Natarajan, Aaron Deykin, Zhaoyang Li, Scott Stecher, Liyu Yang
Publikováno v: Journal of clinical pharmacology. 52(4)
The objective of the study was to evaluate the effect of hepatic impairment on the pharmacokinetics of tonapofylline. Patients with mild or moderate hepatic impairment were enrolled in parallel with demographically matched healthy subjects. All study
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de01b22134abc8b85d3fa5989cc6122c
https://pubmed.ncbi.nlm.nih.gov/21610206
Zobrazit plný text záznamu
7
Safety, Tolerability, and Pharmacokinetics of BG-12 Administered with and without Aspirin: Key Findings from a Randomized, Double-Blind, Placebo-Controlled Trial in Healthy Volunteers (P04.136)
Autor: John O'Gorman, Heidy Russell, Scott Stecher, Ginger L. Milne, Sarah Sheikh, Katherine Dawson, Ron Huang, Mark Novas, Ivan Nestorov
Publikováno v: Neurology. 78:P04.136-P04.136
Objective: To evaluate the safety, tolerability, and pharmacokinetics of BG-12 (dimethyl fumarate) administered with or without aspirin. Background Oral BG-12 is currently being evaluated for treatment of relapsing-remitting multiple sclerosis (RRMS)
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::65b951474c996d0470cb0a30d3083a82
https://doi.org/10.1212/wnl.78.1_meetingabstracts.p04.136
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje